相关实验视频

Updated: Jan 14, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

诱导化疗免疫疗法随后放射治疗在局部发达的头部和部状细胞癌中

Yan Tian¹, Zenan Fan¹, Yong Qin²

¹Department of Oncology, Peking University First Hospital, Beijing, 100034, People's Republic of China.

Cancer management and research

|October 20, 2025

概括

将免疫疗法添加到诱导化疗 (IC) 中,显著改善了局部晚期头支状细胞癌 (LA-HNSCC) 患者的治疗结果. 这种方法有望提高HNSCC患者的治疗疗效.

科学领域:

在瘤学瘤学.
头部和部癌症研究研究
免疫治疗是一种免疫疗法.

背景情况:

头部和部状细胞癌 (HNSCC) 往往是在晚期被诊断出来的.
标准治疗包括手术或化学放射治疗,在晚期病例中有效性有限.

研究的目的:

为了评估在局部发达HNSCC (LA-HNSCC) 诱导化疗 (IC) 添加免疫治疗的疗效.
在现实环境中评估治疗结果,包括反应率和生存率.

主要方法:

一项对42名以前未经治疗的LA-HNSCC患者的现实研究.
患者接受了单独的IC或IC与免疫疗法,随后进行放射治疗.
从2021年1月到2024年10月收集的数据.

主要成果:

免疫治疗+IC组 (N=26) 实现了82.6%的客观反应率 (ORR) 和92.3%的疾病控制率 (DCR).
单独IC组 (N=16) 的ORR为37.5%和DCR为93.8%.
免疫疗法+IC组显示100%的6个月无进展生存 (PFS) 和88.5%的12个月PFS,与92.3%的12个月总生存 (OS).

结论:

将免疫疗法添加到IC中显示出改善LA-HNSCC治疗结果的显著前景.
需要对更大的患者队伍进行进一步的研究来验证这些发现.
免疫疗法与诱导化疗相结合,代表了HNSCC治疗的潜在进展.

关键词:

检查点抑制剂的检查点抑制剂化学免疫疗法化学免疫疗法免疫疗法免疫疗法诱导化疗是一种诱导化疗.局部发达的头部和部状细胞癌.

更多相关视频

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...